{"gene":"HOXB13","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2009,"finding":"HOXB13 physically interacts with the DNA-binding domain of the androgen receptor (AR) and inhibits transcription of genes containing an androgen-response element (ARE), while the AR:HOXB13 complex confers androgen responsiveness to promoters containing a specific HOXB13-response element; HOXB13 and AR also synergize to enhance transcription of genes with a HOX element juxtaposed to an ARE.","method":"Co-immunoprecipitation, reporter transcription assay, siRNA knockdown with proliferation/migration/lipogenesis readouts in prostate cancer cells","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal protein interaction mapped to AR DNA-binding domain, multiple orthogonal functional assays (reporter, knockdown, phenotypic), single lab","pmids":["19917249"],"is_preprint":false},{"year":2004,"finding":"HOXB13 physically interacts with AR and suppresses hormone-mediated AR transcriptional activity in a dose-responsive manner; overexpression of HOXB13 suppresses androgen-stimulated PSA expression and inhibits LNCaP prostate cancer cell growth in an AR-dependent manner.","method":"Co-immunoprecipitation, reporter transcription assay, HOXB13 overexpression/knockdown with PSA expression and cell growth readouts","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, reporter assays, growth assays; replicated by multiple subsequent papers confirming AR interaction","pmids":["15604291"],"is_preprint":false},{"year":2004,"finding":"HOXB13 suppresses growth of PC3 prostate cancer cells through G1 cell cycle arrest by negatively regulating TCF-4 protein expression and downstream targets c-myc and cyclin D1, inhibiting beta-catenin/TCF-mediated transcriptional activity.","method":"Forced HOXB13 expression in HOXB13-negative cells, TCF-4 reporter gene assay, western blot for TCF-4/c-myc/cyclin D1, in vitro and in vivo growth assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus western blot plus cell growth, single lab","pmids":["15126340"],"is_preprint":false},{"year":2010,"finding":"HOXB13 co-localizes with AR in prostate cancer cells and suppresses androgen-stimulated AR activity by interacting with AR; HOXB13 does not bind to AR-responsive elements nor disturb nuclear translocation of AR, acting instead as a non-DNA-binding transcriptional repressor.","method":"Co-immunoprecipitation, reporter assay, immunofluorescence co-localization, immunohistochemistry on prostate cancer specimens","journal":"Anatomy & cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP plus localization assays plus reporter, single lab, moderate methods","pmids":["21267402"],"is_preprint":false},{"year":2010,"finding":"In androgen-free conditions, HOXB13 promotes LNCaP prostate cancer cell proliferation through activation of RB-E2F signaling by inhibiting p21waf expression.","method":"HOXB13 induction/suppression in LNCaP cells, cell proliferation assays, western blot for p21waf and E2F targets","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional KD/OE with molecular pathway read-out (p21/E2F), single lab","pmids":["20504375"],"is_preprint":false},{"year":2013,"finding":"HOXB13 upregulates ZnT zinc output transporters in prostate cancer cells, lowering intracellular zinc concentrations, which reduces IκBα and stimulates nuclear translocation of RelA/p65 to activate NF-κB signaling and promote cell invasion and metastasis.","method":"DNA microarray, zinc concentration measurement, NF-κB reporter, siRNA knockdown of ZnT4, orthotopic mouse metastasis model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (transcriptomics, biochemical, in vivo model), single lab","pmids":["24096478"],"is_preprint":false},{"year":2013,"finding":"HOXB13 confers tamoxifen resistance in ER-positive breast cancer by directly downregulating ERα transcription, and transcriptionally upregulates IL-6 to activate the mTOR pathway via STAT3 phosphorylation, promoting cell proliferation and fibroblast recruitment.","method":"HOXB13 overexpression/knockdown, ChIP, reporter assays, xenograft models, mTOR inhibitor rescue experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding, in vivo xenograft validation, multiple orthogonal methods, single lab","pmids":["23832664"],"is_preprint":false},{"year":2018,"finding":"HOXB13 acts as a pioneer factor for AR splice variant AR-V7 in castration-resistant prostate cancer (CRPC): HoxB13 is universally required for and co-localizes with AR-V7 binding to open chromatin across CRPC genomes, pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes.","method":"ChIP-exo in CRPC cells and patient tissues, Co-IP for physical interaction, HOXB13 silencing with cell growth and AR-V7 cistrome readouts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP-exo (high-resolution genome-wide), Co-IP, validated in both cell lines and patient tissues, functional silencing experiment","pmids":["29844167"],"is_preprint":false},{"year":2020,"finding":"HOXB13 acts as a cofactor of MEIS1 in postnatal cardiomyocytes to regulate cell cycle arrest; calcineurin dephosphorylates HOXB13 at serine-204, causing its nuclear localization and cell cycle arrest; cardiomyocyte-specific deletion of Hoxb13 extends the postnatal window of cardiomyocyte proliferation and reactivates the adult cardiomyocyte cell cycle.","method":"Cardiomyocyte-specific knockout mice, double Meis1-Hoxb13 knockout, ChIP-seq, echocardiography/MRI, phosphatase assay identifying calcineurin-mediated dephosphorylation of Ser204","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic KO, ChIP-seq, in vivo functional readout (cardiac function after MI), post-translational modification mechanistically linked to localization and cell cycle, multiple orthogonal methods","pmids":["32499640"],"is_preprint":false},{"year":2022,"finding":"HOXB13 interacts with histone deacetylase HDAC3 and recruits it to lipogenic enhancers to catalyze histone deacetylation and suppress lipogenic regulators such as fatty acid synthase; the HOXB13 G84E mutation disrupts this HOXB13-HDAC3 interaction, leading to lipid accumulation and increased cell motility and tumor metastasis.","method":"Co-immunoprecipitation for HOXB13-HDAC3 interaction, ChIP-seq, histone deacetylation assays, G84E mutant functional characterization, xenograft metastasis model, fatty acid synthase inhibitor rescue","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP, ChIP-seq, enzymatic assay, mutagenesis with G84E, in vivo model, multiple orthogonal methods in single rigorous study","pmids":["35468964"],"is_preprint":false},{"year":2014,"finding":"The prostate cancer risk SNP rs339331 at 6q22 lies within a functional HOXB13-binding site; the risk T allele increases HOXB13 binding to a transcriptional enhancer, conferring allele-specific upregulation of RFX6 expression.","method":"ChIP-seq for HOXB13 binding, allele-specific reporter assays, HOXB13 knockdown with RFX6 expression readout","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP-seq demonstrating direct binding, allele-specific reporter assay, functional knockdown, multiple orthogonal methods","pmids":["24390282"],"is_preprint":false},{"year":2009,"finding":"A FOXA1-binding 37-bp enhancer element downstream of the Hoxb13 coding region is required for prostate-specific transcriptional activation of Hoxb13; FOXA1 directly occupies this element in human prostate cancer cells.","method":"BAC-based reporter gene deletion analysis in transgenic mice, ChIP for FOXA1 binding, replacement of enhancer element with LoxP site","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo transgenic enhancer deletion plus ChIP validation, multiple complementary genetic approaches","pmids":["20018680"],"is_preprint":false},{"year":2008,"finding":"HDAC4 and YY1 form a complex that is recruited to HOXB13 promoter YY1-binding sites to repress HOXB13 expression via histone deacetylation in AR-negative prostate cancer cells; HDAC inhibitor NaB relieves this repression and induces cell growth arrest.","method":"Co-immunoprecipitation for HDAC4-YY1 complex, ChIP for HDAC4/YY1 at HOXB13 promoter, promoter truncation and point mutation reporter assays","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP, promoter mutagenesis, single lab","pmids":["19013255"],"is_preprint":false},{"year":2012,"finding":"EZH2 recruits DNMT3b to the HOXB13 promoter to form a repression complex mediating DNA methylation and histone methylation; all-trans retinoic acid (ATRA) upregulates HOXB13 by decreasing EZH2 and DNMT3b expression and reducing their interaction with the HOXB13 promoter.","method":"ChIP for EZH2 and DNMT3b at HOXB13 promoter, Co-IP for EZH2-DNMT3b interaction, ATRA treatment with promoter methylation quantification","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus bisulfite methylation analysis, single lab","pmids":["22808286"],"is_preprint":false},{"year":2003,"finding":"Loss-of-function mutations in Hoxb13 in mice cause overgrowth of the caudal spinal cord and tail vertebrae due to increased cell proliferation and decreased apoptosis in the tail bud; Hoxb13 functions as an inhibitor of neuronal cell proliferation and activator of apoptotic pathways in the secondary neural tube.","method":"Hoxb13 knockout mouse generation, beta-galactosidase reporter allele for expression mapping, histological analysis, cell proliferation and apoptosis quantification","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean in vivo KO mouse with defined phenotypic readouts (proliferation/apoptosis), reporter allele expression mapping, well-characterized genetic model","pmids":["12679105"],"is_preprint":false},{"year":2003,"finding":"Hoxb13 is required for normal differentiation and secretory function of the ventral prostate epithelium; loss of Hoxb13 leads to simple cuboidal rather than tall columnar epithelial cells and loss of ventral-specific secretory proteins (p12 and p25); Hoxb13/Hoxd13 double mutants show severe hypoplasia of duct tips, revealing redundancy in prostate morphogenesis.","method":"Hoxb13 loss-of-function mouse, Hoxb13/Hoxd13 double mutant, histological analysis, in situ hybridization for secretory protein expression","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean mouse KO with defined differentiation phenotype and molecular markers, genetic epistasis via double mutant","pmids":["12668621"],"is_preprint":false},{"year":2005,"finding":"HOXB13 suppresses growth of colorectal cancer cells by negatively regulating TCF-4 protein stability and its downstream targets c-myc and cyclin D1, inhibiting beta-catenin/TCF-mediated signaling; HOXB13 expression is lost or diminished in 62% of colorectal tumors.","method":"Forced expression of HOXB13 in CRC cells, TCF-4 reporter assay, western blot for TCF-4/c-myc/cyclin D1, in vitro and in vivo growth suppression assay","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — reporter assay, western blot, functional growth assay, single lab","pmids":["15928669"],"is_preprint":false},{"year":2006,"finding":"HOXB13 is epigenetically silenced by CpG island methylation in renal cell carcinoma (RCC); exogenous HOXB13 expression in RCC cells lacking endogenous HOXB13 suppresses colony formation and induces apoptosis, supporting a tumor suppressor function.","method":"Methylated CpG island amplification/RDA, bisulfite restriction analysis, methyltransferase inhibitor reactivation, exogenous HOXB13 expression with colony formation and apoptosis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — epigenetic silencing mechanistically linked to expression loss and validated functionally, single lab","pmids":["16278676"],"is_preprint":false},{"year":2010,"finding":"DNMT3B directly targets the HOXB13 upstream CpG island for methylation in colon cancer; cells lacking both DNMT1 and DNMT3B show near-complete demethylation of this locus; HOXB13 expression suppresses colon cancer growth in vitro and abolishes tumor growth in nude mice.","method":"ChIP with DNMT3B antibody followed by CpG island microarray, MassARRAY methylation analysis, DNMT1/3B knockout cells, nude mouse xenograft tumor suppression assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-on-chip for DNMT3B binding, genetic knockout validation, in vivo functional assay, single lab","pmids":["20454457"],"is_preprint":false},{"year":2018,"finding":"BRD4 epigenetically promotes HOXB13 expression in CRPC cells; pharmacological dual BET bromodomain-kinase inhibitors suppress HOXB13 mRNA and protein, directly correlating with apoptosis induction and inhibition of CRPC growth.","method":"BRD4 inhibition (pharmacological and genetic), HOXB13 mRNA/protein quantification, cell proliferation/apoptosis assays, integrative transcriptomic analysis","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — genetic and pharmacological BRD4 disruption linked to HOXB13 expression changes and functional phenotype, single lab","pmids":["30242092"],"is_preprint":false},{"year":2018,"finding":"HBXIP prevents chaperone-mediated autophagy (CMA)-dependent degradation of HOXB13 by enhancing HOXB13 acetylation at lysine 277, causing HOXB13 accumulation; HBXIP also acts as a co-activator of HOXB13 to stimulate IL-6 transcription, promoting tamoxifen resistance in breast cancer.","method":"Co-IP, ChIP, luciferase reporter, western blot for acetylation at K277, site-directed mutagenesis of K277, cell viability and xenograft assays","journal":"Journal of hematology & oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, site-directed mutagenesis identifying K277 acetylation site, single lab","pmids":["29471853"],"is_preprint":false},{"year":2022,"finding":"CBP/p300 mediates acetylation of HOXB13 at lysine 13 (K13); acK13-HOXB13 promotes expression of lineage genes (AR, HOXB13), CRPC-promoting genes (ACK1), and angiogenesis genes by establishing tumor-specific super enhancers; loss of K13 acetylation (HOXB13K13A mutant) reduces chromatin binding, self-renewal, and xenograft growth while increasing enzalutamide sensitivity.","method":"Mass spectrometry identification of K13 acetylation, ChIP-seq for super enhancers, HOXB13K13A isogenic mutants, organoid sensitivity assays, xenograft tumor models","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — MS identification of PTM, ChIP-seq, isogenic mutant functional validation in cells and in vivo, multiple orthogonal methods","pmids":["35849143"],"is_preprint":false},{"year":2020,"finding":"MEIS1 tumor-suppressive activity in prostate cancer is dependent on HOXB13; MEIS1 and HOXB13 directly co-regulate proteoglycans including decorin (DCN) as a mechanism of MEIS1-driven tumor suppression, as demonstrated by HOXB13 deletion abolishing MEIS1 anti-tumor effects.","method":"HOXB13 CRISPR deletion in context of MEIS1 expression, ChIP-seq plus RNA-seq integration, in vitro and in vivo xenograft models","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via CRISPR deletion, ChIP-seq plus RNA-seq, in vivo xenograft validation, single lab","pmids":["32553107"],"is_preprint":false},{"year":2013,"finding":"HOXB13 accumulates cells at G1 by promoting ubiquitination and degradation of cyclin D1, reducing pRb phosphorylation; depletion of HOXB13 increases cyclin B1 and CDC25C, activating CDK1 and facilitating G2/M transition.","method":"HOXB13 overexpression and siRNA knockdown in PC-3 and LNCaP cells, cell cycle analysis, western blot for cyclins/pRb/CDC25C, ubiquitination assay for cyclin D1","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple cell cycle readouts with molecular mechanism (ubiquitination), single lab","pmids":["24325868"],"is_preprint":false},{"year":2015,"finding":"HOXB13 and ALX4 form a protein complex in ovarian cancer cells; either protein alone promotes EMT and invasion; both proteins transcriptionally upregulate SLUG expression, and SLUG is required for HOXB13- or ALX4-mediated EMT and invasion.","method":"Co-immunoprecipitation for HOXB13-ALX4 complex, knockdown/overexpression experiments, invasion assays, western blot for SLUG and EMT markers","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP for complex formation, epistasis via SLUG knockdown rescue, single lab","pmids":["25944620"],"is_preprint":false},{"year":2020,"finding":"FTO demethylates m6A modifications in the 3' UTR of HOXB13 mRNA, abolishing YTHDF2-mediated recognition and mRNA decay, thereby increasing HOXB13 protein expression, which activates WNT signaling and promotes endometrial cancer metastasis; WNT inhibitor ICG-001 blocks HOXB13-induced metastasis.","method":"MeRIP-seq for m6A sites, FTO overexpression/knockdown with HOXB13 mRNA stability assays, YTHDF2 interaction studies, in vivo metastasis model, ICG-001 rescue","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP-seq mapping m6A sites plus functional mRNA decay assay plus in vivo rescue, single lab","pmids":["33103587"],"is_preprint":false},{"year":2014,"finding":"HOXB13 transcriptionally suppresses prostate-derived Ets factor (PDEF) expression, leading to upregulation of MMP-9 and survivin and promotion of prostate cancer cell invasion.","method":"DNA microarray, HOXB13 overexpression in PC3 cells, transwell invasion assay, gelatin zymography, western blot for MMP-9 and survivin","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — transcriptomic identification plus functional invasion assay plus molecular validation, single lab","pmids":["24898171"],"is_preprint":false},{"year":2019,"finding":"HOXB13 directly binds to promoters of ABCG1, EZH2, and Slug to upregulate their expression, promoting lung adenocarcinoma metastasis and cisplatin resistance; cisplatin treatment further induces HOXB13 expression, creating a resistance loop.","method":"ChIP for HOXB13 binding at ABCG1/EZH2/Slug promoters, HOXB13 overexpression/knockdown with drug sensitivity assays, xenograft and patient-derived xenograft models","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, PDX model validation, single lab","pmids":["31037158"],"is_preprint":false},{"year":2018,"finding":"HOXB13 binds to the CIP2A gene locus and functionally promotes CIP2A transcription in prostate cancer cells, with synergistic interaction between HOXB13 G84E and CIP2A R229Q variants conferring highest inherited prostate cancer risk.","method":"ChIP for HOXB13 at CIP2A locus, overexpression of variants with cell growth and migration readouts, genotyping cohort studies","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ChIP demonstrating direct binding plus functional assays, validated in multiple cohorts, single lab functional work","pmids":["30181389"],"is_preprint":false},{"year":2005,"finding":"Hoxb13 overexpression in an adult organotypic epidermal model decreases cell proliferation, increases apoptosis, and promotes excessive terminal differentiation characterized by enhanced transglutaminase activity and cornified envelope formation.","method":"Hoxb13 overexpression in organotypic epidermal model, transglutaminase activity assay, apoptosis and proliferation quantification, histological analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — organotypic model with enzymatic activity readout, single lab","pmids":["15964834"],"is_preprint":false},{"year":2019,"finding":"HOXB13 regulates a mitotic protein-kinase interaction network; HOXB13 depletion increases HSPB8 mRNA expression in metastatic CRPC models, and increased HSPB8 expression suppresses CRPC cell migration; HOXB13 co-regulates mitotic kinases including AURKB and MELK.","method":"HOXB13 knockdown in CRPC cell lines, integrative bioinformatics of AR binding sites, HSPB8 overexpression migration assay, expression analysis in circulating tumor cells","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — functional knockdown with migration readout, largely bioinformatics-driven target identification, single lab","pmids":["31273254"],"is_preprint":false},{"year":2021,"finding":"HOXB13 directly binds to and transcriptionally regulates the HOXA11-AS lncRNA promoter; the HOXB13/HOXA11-AS axis regulates CCL2/CCR2 signaling and integrin subunits (ITGAV, ITGB1) relevant to prostate cancer bone metastasis; HOXB13 co-regulates IBSP promoter in combination with HOXA11-AS.","method":"ChIP for HOXB13 at HOXA11-AS promoter, HOXB13 knockdown/overexpression with gene expression and invasion readouts, conditioned medium experiments with osteoblasts","journal":"Genes","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single ChIP experiment plus functional assays, single lab, limited mechanistic depth","pmids":["33514011"],"is_preprint":false},{"year":2003,"finding":"HOXB13 protein is localized predominantly to the cytoplasm throughout fetal skin development, with only partial nuclear localization observed in adult epidermis; in Kaposi's sarcoma-associated epidermis, strong HOXB13 expression is partially nuclear, suggesting context-dependent compartmentalization.","method":"Immunofluorescence/immunohistochemistry on developing and adult skin tissue sections and Kaposi's sarcoma specimens","journal":"Developmental dynamics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — localization by immunostaining only, no functional consequence directly tested, single study","pmids":["12761847"],"is_preprint":false},{"year":2020,"finding":"HOXB13 promotes gastric cancer cell migration and invasion by transcriptionally upregulating IGF-1R, activating the PI3K/AKT/mTOR signaling pathway; FTO suppresses HOXB13 mRNA methylation, increasing HOXB13 protein and thus downstream IGF-1R/PI3K signaling.","method":"MeRIP-seq, luciferase reporter assay for HOXB13-IGF1R regulatory interaction, HOXB13/FTO knockdown with Transwell invasion/migration assays, western blot for PI3K/AKT/mTOR","journal":"Life sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — luciferase reporter plus functional assays, m6A methylation regulation, single lab","pmids":["33894267"],"is_preprint":false},{"year":2022,"finding":"HOXB13 activates PIMREG promoter transcription; elevated PIMREG in turn upregulates RAD51, BRCA1, and CDC25A/B/C while downregulating HIPK2, increasing DNA repair capacity and cell cycle progression to promote HCC drug resistance; HOXB13 acts through PIMREG rather than directly regulating these downstream targets.","method":"Luciferase reporter assay for PIMREG promoter, PIMREG knockdown in HOXB13-overexpressing cells, western blot for DNA repair/cell cycle proteins, in vivo xenograft model","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — luciferase reporter plus epistasis knockdown, single lab, limited mechanistic depth for full pathway","pmids":["35878427"],"is_preprint":false}],"current_model":"HOXB13 is a homeodomain transcription factor that acts as a context-dependent regulator of androgen receptor (AR) signaling in prostate cells: it physically interacts with the AR DNA-binding domain to repress ARE-driven transcription while redirecting AR to HOXB13-response elements, pioneers binding of the constitutively active AR-V7 splice variant to open chromatin in castration-resistant prostate cancer (CRPC), recruits HDAC3 to lipogenic enhancers to suppress fatty acid synthesis (an interaction disrupted by the cancer-predisposing G84E mutation), undergoes CBP/p300-mediated acetylation at K13 and calcineurin-mediated dephosphorylation at S204 (the latter controlling nuclear localization and cell cycle arrest in cardiomyocytes), cooperates with MEIS1 as a cofactor to regulate proteoglycan and proliferation genes, and suppresses the Wnt/TCF4 pathway in colorectal and prostate contexts; its transcriptional activity is itself regulated by a FOXA1-bound prostate-specific enhancer and by YY1-HDAC4-mediated and EZH2-DNMT3b-mediated epigenetic repression."},"narrative":{"mechanistic_narrative":"HOXB13 is a homeodomain transcription factor that functions as a context-dependent regulator of androgen receptor (AR) signaling and a developmental determinant of caudal and prostate tissues [PMID:19917249, PMID:12679105, PMID:12668621]. In prostate cells it physically associates with the AR DNA-binding domain, repressing classical ARE-driven transcription while conferring androgen responsiveness to promoters bearing HOXB13-response elements, and it can act as a non-DNA-binding repressor that does not disturb AR nuclear translocation [PMID:19917249, PMID:15604291, PMID:21267402]. In castration-resistant prostate cancer it serves as a pioneer factor for the constitutively active AR-V7 splice variant, being universally required for and physically interacting with AR-V7 to open chromatin and activate target oncogenes [PMID:29844167]. HOXB13 recruits HDAC3 to lipogenic enhancers to deacetylate histones and suppress fatty acid synthase, an interaction abolished by the cancer-predisposing G84E mutation, which causes lipid accumulation and metastasis [PMID:35468964]. Its own chromatin engagement and lineage program are tuned by CBP/p300-mediated acetylation at K13, which establishes tumor-specific super-enhancers driving AR, ACK1 and angiogenesis genes [PMID:35849143]. HOXB13 also operates as a cofactor of MEIS1, with the two factors co-regulating proteoglycans such as decorin to mediate MEIS1 tumor suppression, and calcineurin-dependent dephosphorylation at S204 controls its nuclear localization and cell-cycle arrest in postnatal cardiomyocytes [PMID:32499640, PMID:32553107]. Across colorectal and prostate contexts HOXB13 suppresses growth by destabilizing TCF-4 and inhibiting beta-catenin/TCF transcriptional output and downstream c-myc and cyclin D1 [PMID:15126340, PMID:15928669]. HOXB13 expression is itself set by a FOXA1-bound prostate-specific enhancer and silenced by YY1-HDAC4 and EZH2-DNMT3b epigenetic complexes [PMID:20018680, PMID:19013255, PMID:22808286]. The prostate cancer risk SNP rs339331 lies within a functional HOXB13-binding enhancer whose risk allele increases HOXB13 binding and RFX6 expression [PMID:24390282].","teleology":[{"year":2003,"claim":"Establishing HOXB13's native developmental function showed it restrains proliferation and promotes apoptosis in caudal tissues and is required for prostate epithelial differentiation, defining its baseline biology before its cancer roles were dissected.","evidence":"Hoxb13 knockout and Hoxb13/Hoxd13 double-mutant mice with histology, reporter expression mapping, and secretory marker analysis","pmids":["12679105","12668621"],"confidence":"High","gaps":["Molecular targets mediating proliferation/apoptosis control in the tail bud not identified","Mechanism of redundancy with Hoxd13 in prostate morphogenesis unresolved"]},{"year":2004,"claim":"The first demonstration that HOXB13 physically binds AR and suppresses hormone-driven AR transcription and prostate cancer cell growth established it as a direct AR-pathway modulator.","evidence":"Co-IP, reporter assays, and overexpression/knockdown with PSA and growth readouts in LNCaP cells","pmids":["15604291"],"confidence":"High","gaps":["Interaction surface on AR not mapped at this stage","Whether repression requires HOXB13 DNA binding unresolved"]},{"year":2004,"claim":"Linking HOXB13 to TCF-4/beta-catenin suppression revealed a growth-arrest mechanism independent of AR, explaining its tumor-suppressive behavior in AR-negative contexts.","evidence":"Forced expression in PC3 cells, TCF-4 reporter, western blot for c-myc/cyclin D1, in vitro and in vivo growth assays","pmids":["15126340"],"confidence":"Medium","gaps":["Direct mechanism by which HOXB13 lowers TCF-4 not defined","Whether effect is transcriptional or post-translational at this stage unclear"]},{"year":2009,"claim":"Mapping the AR-DNA-binding-domain interaction and defining HOXB13-response elements showed HOXB13 both represses ARE genes and redirects AR to a distinct cis-regulatory program, refining its dual transcriptional role.","evidence":"Co-IP mapping to AR DBD, reporter assays, and siRNA knockdown with phenotypic readouts in prostate cancer cells","pmids":["19917249"],"confidence":"High","gaps":["Genome-wide scope of HOXB13/AR co-regulation not established","Structural basis of the DBD interaction not resolved"]},{"year":2009,"claim":"Identifying a FOXA1-bound enhancer required for prostate-specific Hoxb13 transcription explained how HOXB13 expression is restricted to prostate lineage.","evidence":"BAC reporter deletion analysis in transgenic mice and FOXA1 ChIP in human prostate cancer cells","pmids":["20018680"],"confidence":"High","gaps":["Other lineage factors acting at this enhancer not identified","Regulation in non-prostate HOXB13-expressing tissues not addressed"]},{"year":2008,"claim":"Showing YY1-HDAC4 complex recruitment to the HOXB13 promoter identified an epigenetic mechanism silencing HOXB13 in AR-negative prostate cancer.","evidence":"Co-IP for HDAC4-YY1, ChIP at the promoter, promoter mutagenesis reporters, and HDAC inhibitor treatment","pmids":["19013255"],"confidence":"Medium","gaps":["Signals that trigger YY1-HDAC4 recruitment unknown","Relationship to other silencing routes not integrated"]},{"year":2012,"claim":"Demonstrating EZH2-DNMT3b co-recruitment and DNA/histone methylation at the HOXB13 promoter, reversible by ATRA, expanded the epigenetic silencing repertoire and offered a route to reactivation.","evidence":"ChIP for EZH2/DNMT3b, Co-IP for their interaction, and ATRA treatment with bisulfite methylation analysis","pmids":["22808286"],"confidence":"Medium","gaps":["Context determining EZH2-DNMT3b versus YY1-HDAC4 silencing not defined","In vivo relevance of ATRA reactivation untested"]},{"year":2014,"claim":"Connecting the rs339331 prostate cancer risk SNP to a functional HOXB13 binding site provided a direct genetic-mechanistic link between HOXB13 cistrome and inherited disease risk via allele-specific RFX6 regulation.","evidence":"HOXB13 ChIP-seq, allele-specific reporter assays, and knockdown with RFX6 readout","pmids":["24390282"],"confidence":"High","gaps":["Functional role of RFX6 in tumorigenesis not established here","Whether other risk loci are similarly HOXB13-dependent unknown"]},{"year":2018,"claim":"Defining HOXB13 as a pioneer factor for AR-V7 explained how androgen-independent AR signaling is maintained in CRPC, recasting HOXB13 from AR repressor to enabler of constitutive AR variant activity.","evidence":"ChIP-exo in CRPC cells and patient tissues, Co-IP, and HOXB13 silencing with cistrome and growth readouts","pmids":["29844167"],"confidence":"High","gaps":["Determinants switching HOXB13 between AR repression and AR-V7 pioneering not defined","Structural basis of chromatin opening not resolved"]},{"year":2020,"claim":"Identifying HOXB13 as a MEIS1 cofactor and the S204 dephosphorylation switch unified its roles as a cell-cycle and tumor-suppression effector across cardiomyocytes and prostate cancer.","evidence":"Cardiomyocyte-specific knockout mice with ChIP-seq and phosphatase assays; CRISPR HOXB13 deletion with ChIP-seq/RNA-seq and xenografts for MEIS1 dependence","pmids":["32499640","32553107"],"confidence":"High","gaps":["Upstream kinase phosphorylating S204 not identified","Whether the MEIS1-HOXB13 module operates in normal prostate not addressed"]},{"year":2022,"claim":"Characterizing the HOXB13-HDAC3 lipogenic axis and the K13 acetylation mark provided a direct biochemical explanation for how the G84E mutation predisposes to prostate cancer and how HOXB13 establishes oncogenic super-enhancers.","evidence":"Co-IP, ChIP-seq, histone deacetylation and mass-spectrometry PTM assays, isogenic G84E and K13A mutants, and xenograft models","pmids":["35468964","35849143"],"confidence":"High","gaps":["Interplay between K13 acetylation and HDAC3 recruitment not jointly tested","Whether G84E also alters K13 acetylation unknown"]},{"year":2018,"claim":"Post-translational stabilization (HBXIP-driven K277 acetylation blocking chaperone-mediated autophagy) and BRD4-driven transcription identified two routes that elevate HOXB13 abundance in cancer.","evidence":"Co-IP, ChIP, K277 acetylation mutagenesis, and BRD4 genetic/pharmacological disruption with expression and viability readouts","pmids":["29471853","30242092"],"confidence":"Medium","gaps":["Relative contribution of stability versus transcription to HOXB13 levels in vivo unclear","Generality of K277-CMA control across tissues untested"]},{"year":2020,"claim":"Demonstrating FTO/m6A control of HOXB13 mRNA stability added a post-transcriptional layer linking HOXB13 abundance to WNT-driven metastasis.","evidence":"MeRIP-seq, FTO and YTHDF2 manipulation with mRNA stability assays, and in vivo metastasis model with WNT inhibitor rescue","pmids":["33103587"],"confidence":"Medium","gaps":["Single-context (endometrial) finding; prostate relevance not tested","Direct demonstration of YTHDF2-mediated decay limited"]},{"year":null,"claim":"How HOXB13 is molecularly switched between tumor-suppressive (AR repression, TCF-4 destabilization, lipogenic suppression) and oncogenic (AR-V7 pioneering, super-enhancer activation, metastasis) programs in a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of HOXB13 on chromatin or in AR/AR-V7/MEIS1 complexes","Determinants integrating K13/K277 acetylation and S204 phosphorylation into a unified regulatory logic unknown","Cause of context-dependent cytoplasmic versus nuclear localization not mechanistically defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,9,10,21,22,27]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[7,10,21,27,28]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,7,8,21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[32]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,7,2,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[9,10,21,22]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,8,23]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[14,15]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[9,12,13,21]}],"complexes":[],"partners":["AR","MEIS1","HDAC3","CBP/P300","ALX4","HBXIP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92826","full_name":"Homeobox protein Hox-B13","aliases":[],"length_aa":284,"mass_kda":30.7,"function":"Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds preferentially to methylated DNA (PubMed:28473536)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92826/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HOXB13","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HOXB13","total_profiled":1310},"omim":[{"mim_id":"618365","title":"ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 10; ZSCAN10","url":"https://www.omim.org/entry/618365"},{"mim_id":"615392","title":"SCM-LIKE PROTEIN WITH 4 MBT DOMAINS 2; SFMBT2","url":"https://www.omim.org/entry/615392"},{"mim_id":"612659","title":"REGULATORY FACTOR X, 6; RFX6","url":"https://www.omim.org/entry/612659"},{"mim_id":"610997","title":"PROSTATE CANCER, HEREDITARY, 9; HPC9","url":"https://www.omim.org/entry/610997"},{"mim_id":"610787","title":"PRAC2 SMALL NUCLEAR PROTEIN; PRAC2","url":"https://www.omim.org/entry/610787"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":38.7},{"tissue":"prostate","ntpm":77.3}],"url":"https://www.proteinatlas.org/search/HOXB13"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q92826","domains":[{"cath_id":"1.10.10.60","chopping":"224-280","consensus_level":"high","plddt":97.1923,"start":224,"end":280}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92826","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92826-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92826-F1-predicted_aligned_error_v6.png","plddt_mean":61.03},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HOXB13","jax_strain_url":"https://www.jax.org/strain/search?query=HOXB13"},"sequence":{"accession":"Q92826","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92826.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92826/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92826"}},"corpus_meta":[{"pmid":"22236224","id":"PMC_22236224","title":"Germline mutations in HOXB13 and prostate-cancer risk.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22236224","citation_count":530,"is_preprint":false},{"pmid":"27956498","id":"PMC_27956498","title":"H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27956498","citation_count":274,"is_preprint":false},{"pmid":"19917249","id":"PMC_19917249","title":"The homeodomain protein HOXB13 regulates the cellular response to androgens.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19917249","citation_count":184,"is_preprint":false},{"pmid":"24390282","id":"PMC_24390282","title":"A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24390282","citation_count":175,"is_preprint":false},{"pmid":"23812955","id":"PMC_23812955","title":"Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.","date":"2013","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/23812955","citation_count":169,"is_preprint":false},{"pmid":"30082829","id":"PMC_30082829","title":"CiRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/HOXB13.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30082829","citation_count":166,"is_preprint":false},{"pmid":"23064873","id":"PMC_23064873","title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).","date":"2012","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23064873","citation_count":153,"is_preprint":false},{"pmid":"12668621","id":"PMC_12668621","title":"Hoxb13 is required for normal differentiation and secretory function of the ventral prostate.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12668621","citation_count":148,"is_preprint":false},{"pmid":"8756292","id":"PMC_8756292","title":"Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8756292","citation_count":143,"is_preprint":false},{"pmid":"29844167","id":"PMC_29844167","title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29844167","citation_count":131,"is_preprint":false},{"pmid":"12679105","id":"PMC_12679105","title":"Hoxb13 mutations cause overgrowth of caudal spinal cord and tail vertebrae.","date":"2003","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/12679105","citation_count":126,"is_preprint":false},{"pmid":"15604291","id":"PMC_15604291","title":"HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15604291","citation_count":125,"is_preprint":false},{"pmid":"32499640","id":"PMC_32499640","title":"A calcineurin-Hoxb13 axis regulates growth mode of mammalian cardiomyocytes.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32499640","citation_count":119,"is_preprint":false},{"pmid":"22841674","id":"PMC_22841674","title":"A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.","date":"2012","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/22841674","citation_count":111,"is_preprint":false},{"pmid":"17942676","id":"PMC_17942676","title":"HOXB13 promotes ovarian cancer progression.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17942676","citation_count":99,"is_preprint":false},{"pmid":"33103587","id":"PMC_33103587","title":"FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.","date":"2020","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/33103587","citation_count":99,"is_preprint":false},{"pmid":"17308270","id":"PMC_17308270","title":"HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17308270","citation_count":99,"is_preprint":false},{"pmid":"15126340","id":"PMC_15126340","title":"HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15126340","citation_count":92,"is_preprint":false},{"pmid":"35468964","id":"PMC_35468964","title":"HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.","date":"2022","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35468964","citation_count":87,"is_preprint":false},{"pmid":"15583692","id":"PMC_15583692","title":"Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15583692","citation_count":85,"is_preprint":false},{"pmid":"23832664","id":"PMC_23832664","title":"HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23832664","citation_count":84,"is_preprint":false},{"pmid":"25595936","id":"PMC_25595936","title":"Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.","date":"2015","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25595936","citation_count":83,"is_preprint":false},{"pmid":"11150241","id":"PMC_11150241","title":"Expression of Hoxb13 and Hoxc10 in developing and regenerating Axolotl limbs and tails.","date":"2001","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11150241","citation_count":80,"is_preprint":false},{"pmid":"15928669","id":"PMC_15928669","title":"HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15928669","citation_count":79,"is_preprint":false},{"pmid":"9665387","id":"PMC_9665387","title":"Modulation of the human homeobox genes PRX-2 and HOXB13 in scarless fetal wounds.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9665387","citation_count":75,"is_preprint":false},{"pmid":"22718278","id":"PMC_22718278","title":"A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men.","date":"2012","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/22718278","citation_count":74,"is_preprint":false},{"pmid":"23292082","id":"PMC_23292082","title":"HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.","date":"2013","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23292082","citation_count":72,"is_preprint":false},{"pmid":"16278676","id":"PMC_16278676","title":"Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16278676","citation_count":72,"is_preprint":false},{"pmid":"22714738","id":"PMC_22714738","title":"Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.","date":"2012","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22714738","citation_count":71,"is_preprint":false},{"pmid":"20504375","id":"PMC_20504375","title":"HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20504375","citation_count":69,"is_preprint":false},{"pmid":"27018308","id":"PMC_27018308","title":"Tumor-associated macrophage-derived CXCL8 could induce ERα suppression via HOXB13 in endometrial cancer.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27018308","citation_count":66,"is_preprint":false},{"pmid":"29471853","id":"PMC_29471853","title":"Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29471853","citation_count":65,"is_preprint":false},{"pmid":"10517879","id":"PMC_10517879","title":"Androgen-independent expression of hoxb-13 in the mouse prostate.","date":"1999","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/10517879","citation_count":64,"is_preprint":false},{"pmid":"24096478","id":"PMC_24096478","title":"HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24096478","citation_count":63,"is_preprint":false},{"pmid":"29716922","id":"PMC_29716922","title":"MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29716922","citation_count":62,"is_preprint":false},{"pmid":"22781434","id":"PMC_22781434","title":"Association between germline HOXB13 G84E mutation and risk of prostate cancer.","date":"2012","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/22781434","citation_count":60,"is_preprint":false},{"pmid":"20454457","id":"PMC_20454457","title":"HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20454457","citation_count":59,"is_preprint":false},{"pmid":"31827402","id":"PMC_31827402","title":"Circular RNA ITCH suppressed prostate cancer progression by increasing HOXB13 expression via spongy miR-17-5p.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31827402","citation_count":58,"is_preprint":false},{"pmid":"31037158","id":"PMC_31037158","title":"HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31037158","citation_count":56,"is_preprint":false},{"pmid":"28798948","id":"PMC_28798948","title":"HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions.","date":"2017","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28798948","citation_count":53,"is_preprint":false},{"pmid":"17453342","id":"PMC_17453342","title":"Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.","date":"2007","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/17453342","citation_count":49,"is_preprint":false},{"pmid":"26108461","id":"PMC_26108461","title":"The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.","date":"2015","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26108461","citation_count":46,"is_preprint":false},{"pmid":"15756448","id":"PMC_15756448","title":"Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer.","date":"2005","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/15756448","citation_count":45,"is_preprint":false},{"pmid":"23393222","id":"PMC_23393222","title":"The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23393222","citation_count":44,"is_preprint":false},{"pmid":"35031163","id":"PMC_35031163","title":"A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.","date":"2022","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/35031163","citation_count":43,"is_preprint":false},{"pmid":"23129385","id":"PMC_23129385","title":"HOXB13 mutations in a population-based, case-control study of prostate cancer.","date":"2012","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/23129385","citation_count":43,"is_preprint":false},{"pmid":"23396964","id":"PMC_23396964","title":"HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.","date":"2013","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23396964","citation_count":39,"is_preprint":false},{"pmid":"21267402","id":"PMC_21267402","title":"HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression.","date":"2010","source":"Anatomy & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21267402","citation_count":39,"is_preprint":false},{"pmid":"32553107","id":"PMC_32553107","title":"MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32553107","citation_count":38,"is_preprint":false},{"pmid":"25944620","id":"PMC_25944620","title":"HOXB13 and ALX4 induce SLUG expression for the promotion of EMT and cell invasion in ovarian cancer cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25944620","citation_count":36,"is_preprint":false},{"pmid":"26176944","id":"PMC_26176944","title":"Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26176944","citation_count":35,"is_preprint":false},{"pmid":"28555048","id":"PMC_28555048","title":"Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28555048","citation_count":35,"is_preprint":false},{"pmid":"30105866","id":"PMC_30105866","title":"Long noncoding RNA HOXB13-AS1 regulates HOXB13 gene methylation by interacting with EZH2 in glioma.","date":"2018","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30105866","citation_count":34,"is_preprint":false},{"pmid":"33894267","id":"PMC_33894267","title":"HOXB13 promotes gastric cancer cell migration and invasion via IGF-1R upregulation and subsequent activation of PI3K/AKT/mTOR signaling pathway.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33894267","citation_count":34,"is_preprint":false},{"pmid":"25629170","id":"PMC_25629170","title":"Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25629170","citation_count":34,"is_preprint":false},{"pmid":"19013255","id":"PMC_19013255","title":"Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19013255","citation_count":34,"is_preprint":false},{"pmid":"24722062","id":"PMC_24722062","title":"HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24722062","citation_count":33,"is_preprint":false},{"pmid":"25825985","id":"PMC_25825985","title":"HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25825985","citation_count":33,"is_preprint":false},{"pmid":"24026887","id":"PMC_24026887","title":"G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24026887","citation_count":32,"is_preprint":false},{"pmid":"26779768","id":"PMC_26779768","title":"Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.","date":"2016","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/26779768","citation_count":32,"is_preprint":false},{"pmid":"21574054","id":"PMC_21574054","title":"Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification.","date":"2011","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/21574054","citation_count":32,"is_preprint":false},{"pmid":"23334858","id":"PMC_23334858","title":"The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland.","date":"2013","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/23334858","citation_count":32,"is_preprint":false},{"pmid":"32885168","id":"PMC_32885168","title":"ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers.","date":"2020","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32885168","citation_count":31,"is_preprint":false},{"pmid":"31815008","id":"PMC_31815008","title":"Tumor-suppressive function and mechanism of HOXB13 in right-sided colon cancer.","date":"2019","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31815008","citation_count":31,"is_preprint":false},{"pmid":"24146108","id":"PMC_24146108","title":"HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.","date":"2013","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24146108","citation_count":31,"is_preprint":false},{"pmid":"23497539","id":"PMC_23497539","title":"HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.","date":"2013","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/23497539","citation_count":30,"is_preprint":false},{"pmid":"12761847","id":"PMC_12761847","title":"HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development.","date":"2003","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/12761847","citation_count":29,"is_preprint":false},{"pmid":"30242092","id":"PMC_30242092","title":"Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30242092","citation_count":29,"is_preprint":false},{"pmid":"22808286","id":"PMC_22808286","title":"ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22808286","citation_count":29,"is_preprint":false},{"pmid":"23457453","id":"PMC_23457453","title":"Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23457453","citation_count":29,"is_preprint":false},{"pmid":"31273254","id":"PMC_31273254","title":"The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31273254","citation_count":28,"is_preprint":false},{"pmid":"37850574","id":"PMC_37850574","title":"Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.","date":"2023","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37850574","citation_count":27,"is_preprint":false},{"pmid":"31062400","id":"PMC_31062400","title":"HOXB13 promotes proliferation, migration, and invasion of glioblastoma through transcriptional upregulation of lncRNA HOXC-AS3.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31062400","citation_count":27,"is_preprint":false},{"pmid":"23541221","id":"PMC_23541221","title":"Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer.","date":"2013","source":"Cancer epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/23541221","citation_count":26,"is_preprint":false},{"pmid":"28272408","id":"PMC_28272408","title":"Computational Modeling of complete HOXB13 protein for predicting the functional effect of SNPs and the associated role in hereditary prostate cancer.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28272408","citation_count":26,"is_preprint":false},{"pmid":"33531604","id":"PMC_33531604","title":"Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33531604","citation_count":26,"is_preprint":false},{"pmid":"29928325","id":"PMC_29928325","title":"HOXB13 expression and promoter methylation as a candidate biomarker in gastric cancer.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29928325","citation_count":25,"is_preprint":false},{"pmid":"32540218","id":"PMC_32540218","title":"Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.","date":"2020","source":"European urology oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32540218","citation_count":24,"is_preprint":false},{"pmid":"32040869","id":"PMC_32040869","title":"Mutation HOXB13 c.853delT in Martinican prostate cancer patients.","date":"2020","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/32040869","citation_count":23,"is_preprint":false},{"pmid":"20018680","id":"PMC_20018680","title":"A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20018680","citation_count":23,"is_preprint":false},{"pmid":"25206306","id":"PMC_25206306","title":"Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer.","date":"2014","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25206306","citation_count":22,"is_preprint":false},{"pmid":"24325868","id":"PMC_24325868","title":"HOXB13 contributes to G1/S and G2/M checkpoint controls in prostate.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24325868","citation_count":22,"is_preprint":false},{"pmid":"33514011","id":"PMC_33514011","title":"Long Noncoding RNA HOXA11-AS and Transcription Factor HOXB13 Modulate the Expression of Bone Metastasis-Related Genes in Prostate Cancer.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33514011","citation_count":22,"is_preprint":false},{"pmid":"25743797","id":"PMC_25743797","title":"Increased expression of HOXB2 and HOXB13 proteins is associated with HPV infection and cervical cancer progression.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25743797","citation_count":22,"is_preprint":false},{"pmid":"15964834","id":"PMC_15964834","title":"Hoxb13 up-regulates transglutaminase activity and drives terminal differentiation in an epidermal organotypic model.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15964834","citation_count":22,"is_preprint":false},{"pmid":"32681068","id":"PMC_32681068","title":"MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32681068","citation_count":21,"is_preprint":false},{"pmid":"35849143","id":"PMC_35849143","title":"Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.","date":"2022","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/35849143","citation_count":21,"is_preprint":false},{"pmid":"26590121","id":"PMC_26590121","title":"HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.","date":"2015","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/26590121","citation_count":21,"is_preprint":false},{"pmid":"30181389","id":"PMC_30181389","title":"Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30181389","citation_count":20,"is_preprint":false},{"pmid":"24148311","id":"PMC_24148311","title":"Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy.","date":"2014","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/24148311","citation_count":20,"is_preprint":false},{"pmid":"33059643","id":"PMC_33059643","title":"LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.","date":"2020","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33059643","citation_count":19,"is_preprint":false},{"pmid":"24898171","id":"PMC_24898171","title":"HOXB13 regulates the prostate-derived Ets factor: implications for prostate cancer cell invasion.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24898171","citation_count":18,"is_preprint":false},{"pmid":"32830201","id":"PMC_32830201","title":"Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32830201","citation_count":18,"is_preprint":false},{"pmid":"26517352","id":"PMC_26517352","title":"Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26517352","citation_count":17,"is_preprint":false},{"pmid":"28484843","id":"PMC_28484843","title":"HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.","date":"2017","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28484843","citation_count":17,"is_preprint":false},{"pmid":"32923906","id":"PMC_32923906","title":"Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.","date":"2020","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32923906","citation_count":17,"is_preprint":false},{"pmid":"22293681","id":"PMC_22293681","title":"Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer.","date":"2012","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/22293681","citation_count":17,"is_preprint":false},{"pmid":"27626483","id":"PMC_27626483","title":"Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626483","citation_count":15,"is_preprint":false},{"pmid":"35878427","id":"PMC_35878427","title":"Excessive activation of HOXB13/PIMREG axis promotes hepatocellular carcinoma progression and drug resistance.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35878427","citation_count":15,"is_preprint":false},{"pmid":"35557042","id":"PMC_35557042","title":"HucMSC-Ex alleviates inflammatory bowel disease via the lnc78583-mediated miR3202/HOXB13 pathway.","date":"2022","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/35557042","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53701,"output_tokens":8516,"usd":0.144422,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18237,"output_tokens":4762,"usd":0.105118,"stage2_stop_reason":"end_turn"},"total_usd":0.24954,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"HOXB13 physically interacts with the DNA-binding domain of the androgen receptor (AR) and inhibits transcription of genes containing an androgen-response element (ARE), while the AR:HOXB13 complex confers androgen responsiveness to promoters containing a specific HOXB13-response element; HOXB13 and AR also synergize to enhance transcription of genes with a HOX element juxtaposed to an ARE.\",\n      \"method\": \"Co-immunoprecipitation, reporter transcription assay, siRNA knockdown with proliferation/migration/lipogenesis readouts in prostate cancer cells\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal protein interaction mapped to AR DNA-binding domain, multiple orthogonal functional assays (reporter, knockdown, phenotypic), single lab\",\n      \"pmids\": [\"19917249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"HOXB13 physically interacts with AR and suppresses hormone-mediated AR transcriptional activity in a dose-responsive manner; overexpression of HOXB13 suppresses androgen-stimulated PSA expression and inhibits LNCaP prostate cancer cell growth in an AR-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, reporter transcription assay, HOXB13 overexpression/knockdown with PSA expression and cell growth readouts\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, reporter assays, growth assays; replicated by multiple subsequent papers confirming AR interaction\",\n      \"pmids\": [\"15604291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"HOXB13 suppresses growth of PC3 prostate cancer cells through G1 cell cycle arrest by negatively regulating TCF-4 protein expression and downstream targets c-myc and cyclin D1, inhibiting beta-catenin/TCF-mediated transcriptional activity.\",\n      \"method\": \"Forced HOXB13 expression in HOXB13-negative cells, TCF-4 reporter gene assay, western blot for TCF-4/c-myc/cyclin D1, in vitro and in vivo growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus western blot plus cell growth, single lab\",\n      \"pmids\": [\"15126340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HOXB13 co-localizes with AR in prostate cancer cells and suppresses androgen-stimulated AR activity by interacting with AR; HOXB13 does not bind to AR-responsive elements nor disturb nuclear translocation of AR, acting instead as a non-DNA-binding transcriptional repressor.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, immunofluorescence co-localization, immunohistochemistry on prostate cancer specimens\",\n      \"journal\": \"Anatomy & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP plus localization assays plus reporter, single lab, moderate methods\",\n      \"pmids\": [\"21267402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In androgen-free conditions, HOXB13 promotes LNCaP prostate cancer cell proliferation through activation of RB-E2F signaling by inhibiting p21waf expression.\",\n      \"method\": \"HOXB13 induction/suppression in LNCaP cells, cell proliferation assays, western blot for p21waf and E2F targets\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional KD/OE with molecular pathway read-out (p21/E2F), single lab\",\n      \"pmids\": [\"20504375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HOXB13 upregulates ZnT zinc output transporters in prostate cancer cells, lowering intracellular zinc concentrations, which reduces IκBα and stimulates nuclear translocation of RelA/p65 to activate NF-κB signaling and promote cell invasion and metastasis.\",\n      \"method\": \"DNA microarray, zinc concentration measurement, NF-κB reporter, siRNA knockdown of ZnT4, orthotopic mouse metastasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (transcriptomics, biochemical, in vivo model), single lab\",\n      \"pmids\": [\"24096478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HOXB13 confers tamoxifen resistance in ER-positive breast cancer by directly downregulating ERα transcription, and transcriptionally upregulates IL-6 to activate the mTOR pathway via STAT3 phosphorylation, promoting cell proliferation and fibroblast recruitment.\",\n      \"method\": \"HOXB13 overexpression/knockdown, ChIP, reporter assays, xenograft models, mTOR inhibitor rescue experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding, in vivo xenograft validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"23832664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HOXB13 acts as a pioneer factor for AR splice variant AR-V7 in castration-resistant prostate cancer (CRPC): HoxB13 is universally required for and co-localizes with AR-V7 binding to open chromatin across CRPC genomes, pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes.\",\n      \"method\": \"ChIP-exo in CRPC cells and patient tissues, Co-IP for physical interaction, HOXB13 silencing with cell growth and AR-V7 cistrome readouts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP-exo (high-resolution genome-wide), Co-IP, validated in both cell lines and patient tissues, functional silencing experiment\",\n      \"pmids\": [\"29844167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HOXB13 acts as a cofactor of MEIS1 in postnatal cardiomyocytes to regulate cell cycle arrest; calcineurin dephosphorylates HOXB13 at serine-204, causing its nuclear localization and cell cycle arrest; cardiomyocyte-specific deletion of Hoxb13 extends the postnatal window of cardiomyocyte proliferation and reactivates the adult cardiomyocyte cell cycle.\",\n      \"method\": \"Cardiomyocyte-specific knockout mice, double Meis1-Hoxb13 knockout, ChIP-seq, echocardiography/MRI, phosphatase assay identifying calcineurin-mediated dephosphorylation of Ser204\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic KO, ChIP-seq, in vivo functional readout (cardiac function after MI), post-translational modification mechanistically linked to localization and cell cycle, multiple orthogonal methods\",\n      \"pmids\": [\"32499640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HOXB13 interacts with histone deacetylase HDAC3 and recruits it to lipogenic enhancers to catalyze histone deacetylation and suppress lipogenic regulators such as fatty acid synthase; the HOXB13 G84E mutation disrupts this HOXB13-HDAC3 interaction, leading to lipid accumulation and increased cell motility and tumor metastasis.\",\n      \"method\": \"Co-immunoprecipitation for HOXB13-HDAC3 interaction, ChIP-seq, histone deacetylation assays, G84E mutant functional characterization, xenograft metastasis model, fatty acid synthase inhibitor rescue\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP, ChIP-seq, enzymatic assay, mutagenesis with G84E, in vivo model, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"35468964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The prostate cancer risk SNP rs339331 at 6q22 lies within a functional HOXB13-binding site; the risk T allele increases HOXB13 binding to a transcriptional enhancer, conferring allele-specific upregulation of RFX6 expression.\",\n      \"method\": \"ChIP-seq for HOXB13 binding, allele-specific reporter assays, HOXB13 knockdown with RFX6 expression readout\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP-seq demonstrating direct binding, allele-specific reporter assay, functional knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"24390282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A FOXA1-binding 37-bp enhancer element downstream of the Hoxb13 coding region is required for prostate-specific transcriptional activation of Hoxb13; FOXA1 directly occupies this element in human prostate cancer cells.\",\n      \"method\": \"BAC-based reporter gene deletion analysis in transgenic mice, ChIP for FOXA1 binding, replacement of enhancer element with LoxP site\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo transgenic enhancer deletion plus ChIP validation, multiple complementary genetic approaches\",\n      \"pmids\": [\"20018680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HDAC4 and YY1 form a complex that is recruited to HOXB13 promoter YY1-binding sites to repress HOXB13 expression via histone deacetylation in AR-negative prostate cancer cells; HDAC inhibitor NaB relieves this repression and induces cell growth arrest.\",\n      \"method\": \"Co-immunoprecipitation for HDAC4-YY1 complex, ChIP for HDAC4/YY1 at HOXB13 promoter, promoter truncation and point mutation reporter assays\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP, promoter mutagenesis, single lab\",\n      \"pmids\": [\"19013255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EZH2 recruits DNMT3b to the HOXB13 promoter to form a repression complex mediating DNA methylation and histone methylation; all-trans retinoic acid (ATRA) upregulates HOXB13 by decreasing EZH2 and DNMT3b expression and reducing their interaction with the HOXB13 promoter.\",\n      \"method\": \"ChIP for EZH2 and DNMT3b at HOXB13 promoter, Co-IP for EZH2-DNMT3b interaction, ATRA treatment with promoter methylation quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus bisulfite methylation analysis, single lab\",\n      \"pmids\": [\"22808286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Loss-of-function mutations in Hoxb13 in mice cause overgrowth of the caudal spinal cord and tail vertebrae due to increased cell proliferation and decreased apoptosis in the tail bud; Hoxb13 functions as an inhibitor of neuronal cell proliferation and activator of apoptotic pathways in the secondary neural tube.\",\n      \"method\": \"Hoxb13 knockout mouse generation, beta-galactosidase reporter allele for expression mapping, histological analysis, cell proliferation and apoptosis quantification\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean in vivo KO mouse with defined phenotypic readouts (proliferation/apoptosis), reporter allele expression mapping, well-characterized genetic model\",\n      \"pmids\": [\"12679105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Hoxb13 is required for normal differentiation and secretory function of the ventral prostate epithelium; loss of Hoxb13 leads to simple cuboidal rather than tall columnar epithelial cells and loss of ventral-specific secretory proteins (p12 and p25); Hoxb13/Hoxd13 double mutants show severe hypoplasia of duct tips, revealing redundancy in prostate morphogenesis.\",\n      \"method\": \"Hoxb13 loss-of-function mouse, Hoxb13/Hoxd13 double mutant, histological analysis, in situ hybridization for secretory protein expression\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean mouse KO with defined differentiation phenotype and molecular markers, genetic epistasis via double mutant\",\n      \"pmids\": [\"12668621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HOXB13 suppresses growth of colorectal cancer cells by negatively regulating TCF-4 protein stability and its downstream targets c-myc and cyclin D1, inhibiting beta-catenin/TCF-mediated signaling; HOXB13 expression is lost or diminished in 62% of colorectal tumors.\",\n      \"method\": \"Forced expression of HOXB13 in CRC cells, TCF-4 reporter assay, western blot for TCF-4/c-myc/cyclin D1, in vitro and in vivo growth suppression assay\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — reporter assay, western blot, functional growth assay, single lab\",\n      \"pmids\": [\"15928669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HOXB13 is epigenetically silenced by CpG island methylation in renal cell carcinoma (RCC); exogenous HOXB13 expression in RCC cells lacking endogenous HOXB13 suppresses colony formation and induces apoptosis, supporting a tumor suppressor function.\",\n      \"method\": \"Methylated CpG island amplification/RDA, bisulfite restriction analysis, methyltransferase inhibitor reactivation, exogenous HOXB13 expression with colony formation and apoptosis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — epigenetic silencing mechanistically linked to expression loss and validated functionally, single lab\",\n      \"pmids\": [\"16278676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DNMT3B directly targets the HOXB13 upstream CpG island for methylation in colon cancer; cells lacking both DNMT1 and DNMT3B show near-complete demethylation of this locus; HOXB13 expression suppresses colon cancer growth in vitro and abolishes tumor growth in nude mice.\",\n      \"method\": \"ChIP with DNMT3B antibody followed by CpG island microarray, MassARRAY methylation analysis, DNMT1/3B knockout cells, nude mouse xenograft tumor suppression assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-on-chip for DNMT3B binding, genetic knockout validation, in vivo functional assay, single lab\",\n      \"pmids\": [\"20454457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRD4 epigenetically promotes HOXB13 expression in CRPC cells; pharmacological dual BET bromodomain-kinase inhibitors suppress HOXB13 mRNA and protein, directly correlating with apoptosis induction and inhibition of CRPC growth.\",\n      \"method\": \"BRD4 inhibition (pharmacological and genetic), HOXB13 mRNA/protein quantification, cell proliferation/apoptosis assays, integrative transcriptomic analysis\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — genetic and pharmacological BRD4 disruption linked to HOXB13 expression changes and functional phenotype, single lab\",\n      \"pmids\": [\"30242092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HBXIP prevents chaperone-mediated autophagy (CMA)-dependent degradation of HOXB13 by enhancing HOXB13 acetylation at lysine 277, causing HOXB13 accumulation; HBXIP also acts as a co-activator of HOXB13 to stimulate IL-6 transcription, promoting tamoxifen resistance in breast cancer.\",\n      \"method\": \"Co-IP, ChIP, luciferase reporter, western blot for acetylation at K277, site-directed mutagenesis of K277, cell viability and xenograft assays\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, site-directed mutagenesis identifying K277 acetylation site, single lab\",\n      \"pmids\": [\"29471853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CBP/p300 mediates acetylation of HOXB13 at lysine 13 (K13); acK13-HOXB13 promotes expression of lineage genes (AR, HOXB13), CRPC-promoting genes (ACK1), and angiogenesis genes by establishing tumor-specific super enhancers; loss of K13 acetylation (HOXB13K13A mutant) reduces chromatin binding, self-renewal, and xenograft growth while increasing enzalutamide sensitivity.\",\n      \"method\": \"Mass spectrometry identification of K13 acetylation, ChIP-seq for super enhancers, HOXB13K13A isogenic mutants, organoid sensitivity assays, xenograft tumor models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — MS identification of PTM, ChIP-seq, isogenic mutant functional validation in cells and in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"35849143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MEIS1 tumor-suppressive activity in prostate cancer is dependent on HOXB13; MEIS1 and HOXB13 directly co-regulate proteoglycans including decorin (DCN) as a mechanism of MEIS1-driven tumor suppression, as demonstrated by HOXB13 deletion abolishing MEIS1 anti-tumor effects.\",\n      \"method\": \"HOXB13 CRISPR deletion in context of MEIS1 expression, ChIP-seq plus RNA-seq integration, in vitro and in vivo xenograft models\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via CRISPR deletion, ChIP-seq plus RNA-seq, in vivo xenograft validation, single lab\",\n      \"pmids\": [\"32553107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HOXB13 accumulates cells at G1 by promoting ubiquitination and degradation of cyclin D1, reducing pRb phosphorylation; depletion of HOXB13 increases cyclin B1 and CDC25C, activating CDK1 and facilitating G2/M transition.\",\n      \"method\": \"HOXB13 overexpression and siRNA knockdown in PC-3 and LNCaP cells, cell cycle analysis, western blot for cyclins/pRb/CDC25C, ubiquitination assay for cyclin D1\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple cell cycle readouts with molecular mechanism (ubiquitination), single lab\",\n      \"pmids\": [\"24325868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HOXB13 and ALX4 form a protein complex in ovarian cancer cells; either protein alone promotes EMT and invasion; both proteins transcriptionally upregulate SLUG expression, and SLUG is required for HOXB13- or ALX4-mediated EMT and invasion.\",\n      \"method\": \"Co-immunoprecipitation for HOXB13-ALX4 complex, knockdown/overexpression experiments, invasion assays, western blot for SLUG and EMT markers\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP for complex formation, epistasis via SLUG knockdown rescue, single lab\",\n      \"pmids\": [\"25944620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FTO demethylates m6A modifications in the 3' UTR of HOXB13 mRNA, abolishing YTHDF2-mediated recognition and mRNA decay, thereby increasing HOXB13 protein expression, which activates WNT signaling and promotes endometrial cancer metastasis; WNT inhibitor ICG-001 blocks HOXB13-induced metastasis.\",\n      \"method\": \"MeRIP-seq for m6A sites, FTO overexpression/knockdown with HOXB13 mRNA stability assays, YTHDF2 interaction studies, in vivo metastasis model, ICG-001 rescue\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP-seq mapping m6A sites plus functional mRNA decay assay plus in vivo rescue, single lab\",\n      \"pmids\": [\"33103587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HOXB13 transcriptionally suppresses prostate-derived Ets factor (PDEF) expression, leading to upregulation of MMP-9 and survivin and promotion of prostate cancer cell invasion.\",\n      \"method\": \"DNA microarray, HOXB13 overexpression in PC3 cells, transwell invasion assay, gelatin zymography, western blot for MMP-9 and survivin\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — transcriptomic identification plus functional invasion assay plus molecular validation, single lab\",\n      \"pmids\": [\"24898171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HOXB13 directly binds to promoters of ABCG1, EZH2, and Slug to upregulate their expression, promoting lung adenocarcinoma metastasis and cisplatin resistance; cisplatin treatment further induces HOXB13 expression, creating a resistance loop.\",\n      \"method\": \"ChIP for HOXB13 binding at ABCG1/EZH2/Slug promoters, HOXB13 overexpression/knockdown with drug sensitivity assays, xenograft and patient-derived xenograft models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, PDX model validation, single lab\",\n      \"pmids\": [\"31037158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HOXB13 binds to the CIP2A gene locus and functionally promotes CIP2A transcription in prostate cancer cells, with synergistic interaction between HOXB13 G84E and CIP2A R229Q variants conferring highest inherited prostate cancer risk.\",\n      \"method\": \"ChIP for HOXB13 at CIP2A locus, overexpression of variants with cell growth and migration readouts, genotyping cohort studies\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ChIP demonstrating direct binding plus functional assays, validated in multiple cohorts, single lab functional work\",\n      \"pmids\": [\"30181389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Hoxb13 overexpression in an adult organotypic epidermal model decreases cell proliferation, increases apoptosis, and promotes excessive terminal differentiation characterized by enhanced transglutaminase activity and cornified envelope formation.\",\n      \"method\": \"Hoxb13 overexpression in organotypic epidermal model, transglutaminase activity assay, apoptosis and proliferation quantification, histological analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — organotypic model with enzymatic activity readout, single lab\",\n      \"pmids\": [\"15964834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HOXB13 regulates a mitotic protein-kinase interaction network; HOXB13 depletion increases HSPB8 mRNA expression in metastatic CRPC models, and increased HSPB8 expression suppresses CRPC cell migration; HOXB13 co-regulates mitotic kinases including AURKB and MELK.\",\n      \"method\": \"HOXB13 knockdown in CRPC cell lines, integrative bioinformatics of AR binding sites, HSPB8 overexpression migration assay, expression analysis in circulating tumor cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional knockdown with migration readout, largely bioinformatics-driven target identification, single lab\",\n      \"pmids\": [\"31273254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HOXB13 directly binds to and transcriptionally regulates the HOXA11-AS lncRNA promoter; the HOXB13/HOXA11-AS axis regulates CCL2/CCR2 signaling and integrin subunits (ITGAV, ITGB1) relevant to prostate cancer bone metastasis; HOXB13 co-regulates IBSP promoter in combination with HOXA11-AS.\",\n      \"method\": \"ChIP for HOXB13 at HOXA11-AS promoter, HOXB13 knockdown/overexpression with gene expression and invasion readouts, conditioned medium experiments with osteoblasts\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single ChIP experiment plus functional assays, single lab, limited mechanistic depth\",\n      \"pmids\": [\"33514011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HOXB13 protein is localized predominantly to the cytoplasm throughout fetal skin development, with only partial nuclear localization observed in adult epidermis; in Kaposi's sarcoma-associated epidermis, strong HOXB13 expression is partially nuclear, suggesting context-dependent compartmentalization.\",\n      \"method\": \"Immunofluorescence/immunohistochemistry on developing and adult skin tissue sections and Kaposi's sarcoma specimens\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — localization by immunostaining only, no functional consequence directly tested, single study\",\n      \"pmids\": [\"12761847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HOXB13 promotes gastric cancer cell migration and invasion by transcriptionally upregulating IGF-1R, activating the PI3K/AKT/mTOR signaling pathway; FTO suppresses HOXB13 mRNA methylation, increasing HOXB13 protein and thus downstream IGF-1R/PI3K signaling.\",\n      \"method\": \"MeRIP-seq, luciferase reporter assay for HOXB13-IGF1R regulatory interaction, HOXB13/FTO knockdown with Transwell invasion/migration assays, western blot for PI3K/AKT/mTOR\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — luciferase reporter plus functional assays, m6A methylation regulation, single lab\",\n      \"pmids\": [\"33894267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HOXB13 activates PIMREG promoter transcription; elevated PIMREG in turn upregulates RAD51, BRCA1, and CDC25A/B/C while downregulating HIPK2, increasing DNA repair capacity and cell cycle progression to promote HCC drug resistance; HOXB13 acts through PIMREG rather than directly regulating these downstream targets.\",\n      \"method\": \"Luciferase reporter assay for PIMREG promoter, PIMREG knockdown in HOXB13-overexpressing cells, western blot for DNA repair/cell cycle proteins, in vivo xenograft model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — luciferase reporter plus epistasis knockdown, single lab, limited mechanistic depth for full pathway\",\n      \"pmids\": [\"35878427\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HOXB13 is a homeodomain transcription factor that acts as a context-dependent regulator of androgen receptor (AR) signaling in prostate cells: it physically interacts with the AR DNA-binding domain to repress ARE-driven transcription while redirecting AR to HOXB13-response elements, pioneers binding of the constitutively active AR-V7 splice variant to open chromatin in castration-resistant prostate cancer (CRPC), recruits HDAC3 to lipogenic enhancers to suppress fatty acid synthesis (an interaction disrupted by the cancer-predisposing G84E mutation), undergoes CBP/p300-mediated acetylation at K13 and calcineurin-mediated dephosphorylation at S204 (the latter controlling nuclear localization and cell cycle arrest in cardiomyocytes), cooperates with MEIS1 as a cofactor to regulate proteoglycan and proliferation genes, and suppresses the Wnt/TCF4 pathway in colorectal and prostate contexts; its transcriptional activity is itself regulated by a FOXA1-bound prostate-specific enhancer and by YY1-HDAC4-mediated and EZH2-DNMT3b-mediated epigenetic repression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HOXB13 is a homeodomain transcription factor that functions as a context-dependent regulator of androgen receptor (AR) signaling and a developmental determinant of caudal and prostate tissues [#0, #14, #15]. In prostate cells it physically associates with the AR DNA-binding domain, repressing classical ARE-driven transcription while conferring androgen responsiveness to promoters bearing HOXB13-response elements, and it can act as a non-DNA-binding repressor that does not disturb AR nuclear translocation [#0, #1, #3]. In castration-resistant prostate cancer it serves as a pioneer factor for the constitutively active AR-V7 splice variant, being universally required for and physically interacting with AR-V7 to open chromatin and activate target oncogenes [#7]. HOXB13 recruits HDAC3 to lipogenic enhancers to deacetylate histones and suppress fatty acid synthase, an interaction abolished by the cancer-predisposing G84E mutation, which causes lipid accumulation and metastasis [#9]. Its own chromatin engagement and lineage program are tuned by CBP/p300-mediated acetylation at K13, which establishes tumor-specific super-enhancers driving AR, ACK1 and angiogenesis genes [#21]. HOXB13 also operates as a cofactor of MEIS1, with the two factors co-regulating proteoglycans such as decorin to mediate MEIS1 tumor suppression, and calcineurin-dependent dephosphorylation at S204 controls its nuclear localization and cell-cycle arrest in postnatal cardiomyocytes [#8, #22]. Across colorectal and prostate contexts HOXB13 suppresses growth by destabilizing TCF-4 and inhibiting beta-catenin/TCF transcriptional output and downstream c-myc and cyclin D1 [#2, #16]. HOXB13 expression is itself set by a FOXA1-bound prostate-specific enhancer and silenced by YY1-HDAC4 and EZH2-DNMT3b epigenetic complexes [#11, #12, #13]. The prostate cancer risk SNP rs339331 lies within a functional HOXB13-binding enhancer whose risk allele increases HOXB13 binding and RFX6 expression [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing HOXB13's native developmental function showed it restrains proliferation and promotes apoptosis in caudal tissues and is required for prostate epithelial differentiation, defining its baseline biology before its cancer roles were dissected.\",\n      \"evidence\": \"Hoxb13 knockout and Hoxb13/Hoxd13 double-mutant mice with histology, reporter expression mapping, and secretory marker analysis\",\n      \"pmids\": [\"12679105\", \"12668621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets mediating proliferation/apoptosis control in the tail bud not identified\", \"Mechanism of redundancy with Hoxd13 in prostate morphogenesis unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The first demonstration that HOXB13 physically binds AR and suppresses hormone-driven AR transcription and prostate cancer cell growth established it as a direct AR-pathway modulator.\",\n      \"evidence\": \"Co-IP, reporter assays, and overexpression/knockdown with PSA and growth readouts in LNCaP cells\",\n      \"pmids\": [\"15604291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction surface on AR not mapped at this stage\", \"Whether repression requires HOXB13 DNA binding unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linking HOXB13 to TCF-4/beta-catenin suppression revealed a growth-arrest mechanism independent of AR, explaining its tumor-suppressive behavior in AR-negative contexts.\",\n      \"evidence\": \"Forced expression in PC3 cells, TCF-4 reporter, western blot for c-myc/cyclin D1, in vitro and in vivo growth assays\",\n      \"pmids\": [\"15126340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism by which HOXB13 lowers TCF-4 not defined\", \"Whether effect is transcriptional or post-translational at this stage unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping the AR-DNA-binding-domain interaction and defining HOXB13-response elements showed HOXB13 both represses ARE genes and redirects AR to a distinct cis-regulatory program, refining its dual transcriptional role.\",\n      \"evidence\": \"Co-IP mapping to AR DBD, reporter assays, and siRNA knockdown with phenotypic readouts in prostate cancer cells\",\n      \"pmids\": [\"19917249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide scope of HOXB13/AR co-regulation not established\", \"Structural basis of the DBD interaction not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying a FOXA1-bound enhancer required for prostate-specific Hoxb13 transcription explained how HOXB13 expression is restricted to prostate lineage.\",\n      \"evidence\": \"BAC reporter deletion analysis in transgenic mice and FOXA1 ChIP in human prostate cancer cells\",\n      \"pmids\": [\"20018680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other lineage factors acting at this enhancer not identified\", \"Regulation in non-prostate HOXB13-expressing tissues not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing YY1-HDAC4 complex recruitment to the HOXB13 promoter identified an epigenetic mechanism silencing HOXB13 in AR-negative prostate cancer.\",\n      \"evidence\": \"Co-IP for HDAC4-YY1, ChIP at the promoter, promoter mutagenesis reporters, and HDAC inhibitor treatment\",\n      \"pmids\": [\"19013255\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signals that trigger YY1-HDAC4 recruitment unknown\", \"Relationship to other silencing routes not integrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating EZH2-DNMT3b co-recruitment and DNA/histone methylation at the HOXB13 promoter, reversible by ATRA, expanded the epigenetic silencing repertoire and offered a route to reactivation.\",\n      \"evidence\": \"ChIP for EZH2/DNMT3b, Co-IP for their interaction, and ATRA treatment with bisulfite methylation analysis\",\n      \"pmids\": [\"22808286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context determining EZH2-DNMT3b versus YY1-HDAC4 silencing not defined\", \"In vivo relevance of ATRA reactivation untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connecting the rs339331 prostate cancer risk SNP to a functional HOXB13 binding site provided a direct genetic-mechanistic link between HOXB13 cistrome and inherited disease risk via allele-specific RFX6 regulation.\",\n      \"evidence\": \"HOXB13 ChIP-seq, allele-specific reporter assays, and knockdown with RFX6 readout\",\n      \"pmids\": [\"24390282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of RFX6 in tumorigenesis not established here\", \"Whether other risk loci are similarly HOXB13-dependent unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defining HOXB13 as a pioneer factor for AR-V7 explained how androgen-independent AR signaling is maintained in CRPC, recasting HOXB13 from AR repressor to enabler of constitutive AR variant activity.\",\n      \"evidence\": \"ChIP-exo in CRPC cells and patient tissues, Co-IP, and HOXB13 silencing with cistrome and growth readouts\",\n      \"pmids\": [\"29844167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants switching HOXB13 between AR repression and AR-V7 pioneering not defined\", \"Structural basis of chromatin opening not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying HOXB13 as a MEIS1 cofactor and the S204 dephosphorylation switch unified its roles as a cell-cycle and tumor-suppression effector across cardiomyocytes and prostate cancer.\",\n      \"evidence\": \"Cardiomyocyte-specific knockout mice with ChIP-seq and phosphatase assays; CRISPR HOXB13 deletion with ChIP-seq/RNA-seq and xenografts for MEIS1 dependence\",\n      \"pmids\": [\"32499640\", \"32553107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream kinase phosphorylating S204 not identified\", \"Whether the MEIS1-HOXB13 module operates in normal prostate not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Characterizing the HOXB13-HDAC3 lipogenic axis and the K13 acetylation mark provided a direct biochemical explanation for how the G84E mutation predisposes to prostate cancer and how HOXB13 establishes oncogenic super-enhancers.\",\n      \"evidence\": \"Co-IP, ChIP-seq, histone deacetylation and mass-spectrometry PTM assays, isogenic G84E and K13A mutants, and xenograft models\",\n      \"pmids\": [\"35468964\", \"35849143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between K13 acetylation and HDAC3 recruitment not jointly tested\", \"Whether G84E also alters K13 acetylation unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Post-translational stabilization (HBXIP-driven K277 acetylation blocking chaperone-mediated autophagy) and BRD4-driven transcription identified two routes that elevate HOXB13 abundance in cancer.\",\n      \"evidence\": \"Co-IP, ChIP, K277 acetylation mutagenesis, and BRD4 genetic/pharmacological disruption with expression and viability readouts\",\n      \"pmids\": [\"29471853\", \"30242092\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of stability versus transcription to HOXB13 levels in vivo unclear\", \"Generality of K277-CMA control across tissues untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating FTO/m6A control of HOXB13 mRNA stability added a post-transcriptional layer linking HOXB13 abundance to WNT-driven metastasis.\",\n      \"evidence\": \"MeRIP-seq, FTO and YTHDF2 manipulation with mRNA stability assays, and in vivo metastasis model with WNT inhibitor rescue\",\n      \"pmids\": [\"33103587\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-context (endometrial) finding; prostate relevance not tested\", \"Direct demonstration of YTHDF2-mediated decay limited\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HOXB13 is molecularly switched between tumor-suppressive (AR repression, TCF-4 destabilization, lipogenic suppression) and oncogenic (AR-V7 pioneering, super-enhancer activation, metastasis) programs in a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of HOXB13 on chromatin or in AR/AR-V7/MEIS1 complexes\", \"Determinants integrating K13/K277 acetylation and S204 phosphorylation into a unified regulatory logic unknown\", \"Cause of context-dependent cytoplasmic versus nuclear localization not mechanistically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 9, 10, 21, 22, 27]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [7, 10, 21, 27, 28]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": [6, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 7, 8, 21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 7, 2, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [9, 10, 21, 22]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 8, 23]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [14, 15]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [9, 12, 13, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AR\", \"MEIS1\", \"HDAC3\", \"CBP/p300\", \"ALX4\", \"HBXIP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}